Comparative Pharmacology
Head-to-head clinical analysis: JUNIOR STRENGTH IBUPROFEN versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNIOR STRENGTH IBUPROFEN versus NAPROSYN.
JUNIOR STRENGTH IBUPROFEN vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category D/X
Category C
NSAID
NSAID